FDA Approved: CINQAIR — Original Application (Teva Respiratory, LLC)

View source ↗

Summary

FDA approved CINQAIR (reslizumab) as add-on maintenance therapy for adults with severe asthma with an eosinophilic phenotype.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CINQAIR (Reslizumab)

Snippet

ORIG AP for CINQAIR (RESLIZUMAB)